357 related articles for article (PubMed ID: 25803691)
21. Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
Casula M; Paliogiannis P; Ayala F; De Giorgi V; Stanganelli I; Mandalà M; Colombino M; Manca A; Sini MC; Caracò C; Ascierto PA; Satta RR; ; Lissia A; Cossu A; Palmieri G;
BMC Cancer; 2019 Aug; 19(1):772. PubMed ID: 31382929
[TBL] [Abstract][Full Text] [Related]
22. Exploring the hereditary background of renal cancer in Denmark.
Christensen MB; Wadt K; Jensen UB; Lautrup CK; Bojesen A; Krogh LN; Overeem Hansen TV; Gerdes AM
PLoS One; 2019; 14(4):e0215725. PubMed ID: 31034483
[TBL] [Abstract][Full Text] [Related]
23. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
Potrony M; Puig-Butille JA; Ribera-Sola M; Iyer V; Robles-Espinoza CD; Aguilera P; Carrera C; Malvehy J; Badenas C; Landi MT; Adams DJ; Puig S
Br J Dermatol; 2019 Jul; 181(1):105-113. PubMed ID: 30451293
[TBL] [Abstract][Full Text] [Related]
24. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D
Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182
[TBL] [Abstract][Full Text] [Related]
25. Melanoma susceptibility genes and risk assessment.
Marzuka-Alcalá A; Gabree MJ; Tsao H
Methods Mol Biol; 2014; 1102():381-93. PubMed ID: 24258989
[TBL] [Abstract][Full Text] [Related]
26. High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium.
Pellegrini C; Cardelli L; Ghiorzo P; Pastorino L; Potrony M; García-Casado Z; Elefanti L; Stefanaki I; Mastrangelo M; Necozione S; Aguilera P; Rodríguez-Hernández A; Di Nardo L; Rocco T; Del Regno L; Badenas C; Carrera C; Malvehy J; Requena C; Bañuls J; Stratigos AJ; Peris K; Menin C; Calista D; Nagore E; Puig S; Landi MT; Fargnoli MC
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2498-2508. PubMed ID: 37611275
[TBL] [Abstract][Full Text] [Related]
27. A Single Center Retrospective Review of Patients from Central Italy Tested for Melanoma Predisposition Genes.
De Simone P; Bottillo I; Valiante M; Iorio A; De Bernardo C; Majore S; D'Angelantonio D; Valentini T; Sperduti I; Piemonte P; Eibenschutz L; Ferrari A; Carbone A; Buccini P; Paiardini A; Silipo V; Frascione P; Grammatico P
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322357
[TBL] [Abstract][Full Text] [Related]
28. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.
Puntervoll HE; Yang XR; Vetti HH; Bachmann IM; Avril MF; Benfodda M; Catricalà C; Dalle S; Duval-Modeste AB; Ghiorzo P; Grammatico P; Harland M; Hayward NK; Hu HH; Jouary T; Martin-Denavit T; Ozola A; Palmer JM; Pastorino L; Pjanova D; Soufir N; Steine SJ; Stratigos AJ; Thomas L; Tinat J; Tsao H; Veinalde R; Tucker MA; Bressac-de Paillerets B; Newton-Bishop JA; Goldstein AM; Akslen LA; Molven A
J Med Genet; 2013 Apr; 50(4):264-70. PubMed ID: 23384855
[TBL] [Abstract][Full Text] [Related]
29. Novel CDKN2A mutation detected in Spanish melanoma pedigree.
de Torre C; Martínez-Escribano J
Exp Dermatol; 2010 Aug; 19(8):e333-5. PubMed ID: 20653773
[TBL] [Abstract][Full Text] [Related]
30. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
[TBL] [Abstract][Full Text] [Related]
31. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
[TBL] [Abstract][Full Text] [Related]
32. CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.
Karagianni F; Njauw CN; Kypreou KP; Stergiopoulou A; Plaka M; Polydorou D; Chasapi V; Pappas L; Stratigos IA; Champsas G; Panagiotou P; Gogas H; Evangelou E; Tsao H; Stratigos AJ; Stefanaki I
Acta Derm Venereol; 2018 Oct; 98(9):862-866. PubMed ID: 29774366
[TBL] [Abstract][Full Text] [Related]
33. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
[TBL] [Abstract][Full Text] [Related]
34. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
[TBL] [Abstract][Full Text] [Related]
35. Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.
Sargen MR; Pfeiffer RM; Yang XR; Tucker MA; Goldstein AM
J Invest Dermatol; 2020 Jan; 140(1):174-181.e3. PubMed ID: 31326397
[TBL] [Abstract][Full Text] [Related]
36. 3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.
Tovar-Parra D; Gil-Quiñones SR; Nova J; Gutiérrez-Castañeda LD
In Vivo; 2021; 35(3):1529-1536. PubMed ID: 33910831
[TBL] [Abstract][Full Text] [Related]
37. Influence of loss of function MC1R variants in genetic susceptibility of familial melanoma in Spain.
de Torre C; Garcia-Casado Z; Martínez-Escribano JA; Botella-Estrada R; Bañuls J; Oliver V; Mercader P; Azaña JM; Frias J; Nagore E
Melanoma Res; 2010 Aug; 20(4):342-8. PubMed ID: 20539244
[TBL] [Abstract][Full Text] [Related]
38. Genetic and environmental factors in cutaneous malignant melanoma.
Bressac-de-Paillerets B; Avril MF; Chompret A; Demenais F
Biochimie; 2002 Jan; 84(1):67-74. PubMed ID: 11900878
[TBL] [Abstract][Full Text] [Related]
39. CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
Orlow I; Begg CB; Cotignola J; Roy P; Hummer AJ; Clas BA; Mujumdar U; Canchola R; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Wilcox H; Busam K; From L; Berwick M;
J Invest Dermatol; 2007 May; 127(5):1234-43. PubMed ID: 17218939
[TBL] [Abstract][Full Text] [Related]
40. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
Bruno W; Pastorino L; Ghiorzo P; Andreotti V; Martinuzzi C; Menin C; Elefanti L; Stagni C; Vecchiato A; Rodolfo M; Maurichi A; Manoukian S; De Giorgi V; Savarese I; Gensini F; Borgognoni L; Testori A; Spadola G; Mandalà M; Imberti G; Savoia P; Astrua C; Ronco AM; Farnetti A; Tibiletti MG; Lombardo M; Palmieri G; Ayala F; Ascierto P; Ghigliotti G; Muggianu M; Spagnolo F; Picasso V; Tanda ET; Queirolo P; Bianchi-Scarrà G
J Am Acad Dermatol; 2016 Feb; 74(2):325-32. PubMed ID: 26775776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]